Latest news
Cary company ends $160M drug collaboration - The Business JournalsThe Business Journals · Thu, 30 Jul 2026 11:17:00 GMTChiesi retreats from Gossamer PAH programme after Phase 3 miss - European Biotechnology MagazineEuropean Biotechnology Magazine · Tue, 28 Jul 2026 07:00:00 GMTAfter missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration - Fierce BiotechFierce Biotech · Mon, 27 Jul 2026 07:00:00 GMTGossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update - Business WireBusiness Wire · Mon, 27 Jul 2026 07:00:00 GMTGossamer regains rights to lung disease asset from Chiesi after Phase 3 fail - biospace.combiospace.com · Mon, 27 Jul 2026 07:00:00 GMT